Pannexins serve an important role in the regulation of extracellular neuronal regenerative currents and cellular signal transduction of glial cells; however, the effects of pannexins in various cerebrovascular diseases have not been reported. The present study focused on the expression and influence of pannexins in a rat model of intracerebral hemorrhage (ICH), and confirmed that pannexins (including Pannexin-1, Pannexin-2 and Pannexin-3) are expressed in rat brain tissues. However, only the expression of Pannexin-1 was significantly increased and peaked 48 h post-ICH. Following treatment with carbenoxolone (CBX), which is an inhibitor of Pannexin-1, apoptosis and neuronal degeneration in the brain tissues around the ICH hematoma decreased. The extent of secondary brain injury due to ICH was also alleviated. Compared with rats in the ICH-only group, recovery of neurocognitive functions improved significantly in the CBX-treated groups.
Introduction
Non-traumatic intracerebral hemorrhage (ICH) is the second most common type of stroke and is associated with high mortality and high morbidity; 50-70% of survivors suffer from paralysis, aphasia and severe disability (1, 2) . Previous studies have demonstrated that brain damage following ICH is due not only to hematoma mass effect and its direct damage to the surrounding brain tissues, but also to secondary brain injury. In addition, apoptosis and degeneration of neurons post-ICH are important factors in secondary brain injury (3, 4) . Following ICH, there is an increase in the local concentration of glutamate, which overstimulates N-methyl-D-aspartate receptors (NMDARs) in the brain (5) ; this leads to an increase in intracellular Ca 2+ and neuron death, suggesting that NMDARs serve an important role in neuronal apoptosis post-ICH.
Pannexins were discovered in vertebrates by Panchin et al in 2000 (6) , and there are three subtypes: Pannexin-1, Pannexin-2 and Pannexin-3. Pannexins exhibit sequence homology to the invertebrate family of gap junction proteins called innexins (6) . Pannexin-1 is a non-selective ion channel that is widely distributed in various tissues and is involved in several important physiological and pathophysiological functions. Pannexin-l may be part of the postsynaptic channel complex and may regulate postsynaptic activity through the formation of hemichannels (7) . Pannexin-l directly mediates the release of ATP, adjusts the extracellular regenerative currents in neurons, and serves an important role in signal transduction in glial cells (8, 9) . Furthermore, Pannexin-1 channels can be activated by ischemia, as indicated by a previous report that demonstrated that during ischemic stroke, the Pannexin-1 hemichannel opening in neurons increases after hypoxic-ischemic stress injury (10) . Another study revealed that the addition of a Pannexin-1 inhibitor to hippocampal slice cultures significantly reduced the activation of caspase-3 and neuronal cell death (11) . In addition, Pannexin-1 channels have been revealed to be activated by NMDARs (12, 13) , which further suggests an important role for Pannexin-1 in neuronal apoptosis following ICH. However, little is currently known regarding the role of Pannexin-1 post-ICH. The present study aimed to explore the expression and the role of Pannexin-1 post-ICH, which, to the best of our knowledge, has not previously been reported. Rat ICH model. A total of 146 male Sprague-Dawley rats (weight, 250-300 g) were purchased from the Animal Center of Soochow University (Suzhou, China) and were raised on a 12-h dark-light cycle with free access to food and water. They were anesthetized with an intraperitoneal injection of pentobarbital (45 mg/kg; Sigma-Aldrich; Merck Millipore, Darmstadt, Germany). Core temperature was maintained at 37˚C using a feedback-controlled heating pad. Rats were positioned in a stereotactic frame (David Kopf Instruments, Tujunga, CA, USA) and a cranial burr hole (1 mm) was drilled on the right coronal suture, 3.5 mm lateral to midline. A 30-gauge needle was introduced through the burr hole into the caudate nucleus, 3.5 mm lateral to midline and 0.2 mm anterior to the bregma, and to a depth of 5.5 mm below the surface of the skull. A microinjector was used to infuse 1 µl buffered saline containing 0.23 units type VII collagenase (Merck Millipore) over 5 min, to break up the basement of vessels and cause internal bleeding. The needle was kept in place for an additional 5 min post-injection to avoid reflux. Sham controls only had an intracerebral needle insertion. Following injection, the needle was removed, the burr hole was filled with bone wax and the skin incision was closed with sutures (14, 15) . Animals were then re-anesthetized as above and perfused for 5 min through the left cardiac ventricle with 0.9% NaCl solution, until effluent from the right atrium was clear, the brain was removed and a coronal tissue slice (3 mm) was cut 4 mm from the frontal pole. Two tissue samples, the ipsilateral and the contralateral cortex, were obtained from each brain.
Materials and methods

Animals
Experimental design. In experiment 1 (Fig. 1A) , 42 of the 54 rats survived and were assigned randomly into 7 groups (n=6/group): 1 sham group (control) and 6 post-ICH groups (6, 12, 24, 48 and 72 h, and 7 days). The animals in the post-ICH groups were subjected to experimental induction of ICH on day 0 and were sacrificed via the aforementioned procedure, after 6, 12, 24, 48, 72 h and 7 days, respectively. In experiment 2 (Fig. 1B) , 72 of the 92 rats survived and were assigned randomly into 4 groups (n=18/group): Sham group; ICH group; ICH + low concentration carbenoxolone (CBX-L; cat. no. A8389; 10 mg/kg; ApexBio Technology, Houstoun, TX, USA) group; and ICH + high concentration CBX (CBX-H; 20 mg/kg) group. The concentration of CBX treatment used was according to a previous study (16) . A CBX stock solution was diluted to 50 mg/ml in sterile saline; the required concentration for each group was then prepared prior to intraperitoneal injection, which occurred 1 h post-ICH induction. A total of 6 rats were selected randomly from each group and sacrificed using the aforementioned procedure, 48 h post-ICH. An additional 6 rats were used to evaluate brain edema and the remaining rats underwent nerve function score tests 48 h following ICH.
Western blot analysis. Brain tissue samples from the ipsilateral and contralateral cortex were mechanically lysed in lysis buffer containing 20 mmol Tris (pH 7.6), 0.2% SDS, 1% Triton X-100, 1% deoxycholate, 1 mmol phenylmethylsulfonyl fluoride and 0.11 U/ml aprotinin (Merck Millipore). The lysates were centrifuged at 12,000 x g for 20 min at 4˚C, and the protein concentration was estimated using the Bradford method. Samples (60 µg) were separated by 10% SDS-PAGE and electrotransferred onto a nitrocellulose membrane (Merck Millipore). The membranes were blocked with 5% non-fat milk for 1 h at room temperature and then incubated with primary antibodies against Pannexin-1 (cat. no. ab124131; Abcam, Cambridge, MA, USA), Pannexin-2 (cat. no. sc-51384; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), Pannexin-3 (cat. no. ab98093; Abcam), active-caspase-3 (cat. no. ab2302; Abcam) or albumin (cat. no. ab207327; Abcam) at dilutions of 1:500 in 5% bovine serum albumin (BSA; Beyotime Institute of Biotechnology, Haimen, China) in TBS + 0.1% Tween-20 overnight at 4˚C. GAPDH (1:6,000; Merck Millipore) was used as a loading control. The membranes were washed 3 times for 5 min each in TBS + 0.1% Tween-20 and then incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies (cat. no. SC-2004; 1:5,000 in 5% BSA; Santa Cruz Biotechnology, Inc.) for 2 h at room temperature. Finally, protein bands were visualized using enhanced chemiluminescence (ECL; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and were exposed to X-ray film. Relative changes in protein expression were estimated from the mean pixel density using UN-SCAN-IT, normalized to β-actin, and calculated as target protein expression/β-actin expression ratios.
Immunofluorescence microscopy. Following collection, brain tissue samples from the ipsilateral cortex were embedded in Tissue-Tek Optimal Cutting Temperature Embedding Compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan). Sections 4 µm thick were sliced and blocked with 5% normal fetal bovine serum in PBS containing 0.1% Triton X-100 for 2 h at room temperature. Following this, sections (4 µm) were then incubated with primary antibodies against Pannexin-1, Pannexin-2 or Pannexin-3 and Neuronal nuclei (NeuN; cat. no. ab104224; Abcam) overnight at 4˚C. Following this, sections were washed three times with PBS for 45 min and were immunolabeled with the appropriate secondary antibodies (Alexa Fluor 488, cat. no. A21206 and Alexa Fluor 555, cat. no. A31570; 1:200; Invitrogen, Thermo Fisher Scientific, Inc.) for 1 h at room temperature. The slides were washed with PBS again three times for 45 min prior to counterstaining with DAPI to stain the nuclei, for 2 min. A total of 3 random sections from each rat were examined and imaged using a fluorescence microscope (Olympus Corporation, Tokyo, Japan). Relative fluorescence intensity was analyzed using ImageJ software version 2 (National Institutes of Health, Bethesda, MA, USA).
Neurobehavioral testing and neurological scoring. Three behavioral activity examinations were performed 48 h post-ICH on 24 rats that were separated into 4 groups (n=6/group: Sham; ICH; ICH + CBX-L; and ICH + CBX-H), to record appetite, activity and neurological deficits using the scoring system reported previously (17) . The standard of behavior and activity scores are shown in Table I .
Brain edema and blood-brain barrier (BBB) integrity.
Brain water content was evaluated using the wet/dry weight method as previously described (18), and BBB integrity was measured by evaluating albumin levels in the ipsilateral cortex, detected via western blotting. To assess brain water content, 24 rats were separated into 4 groups (n=6/group): Sham; ICH; ICH + CBX-L; and ICH + CBX-H. Rats were anesthetized with an intraperitoneal injection of 45 mg/kg pentobarbital and decapitated 48 h post-ICH. Brains were removed, the olfactory bulbs, cerebella and brain stems were discarded, and the contralateral and ipsilateral hemispheres were separated. Each sample was weighed to obtain the wet weight and then dried in an oven at 100˚C for 24 h to obtain the dry weight. Water content was expressed as a percentage of the wet weight: (wet weight -dry weight)/wet weight x100%. described (19) . Briefly, brain sections were incubated in 100% ethanol for 3 min, 70% ethanol for 1 min and then washed with deionized water. Sections were incubated for 10 min in 0.06% potassium permanganate followed by 60 min in Fluoro-Jade B solution (Histo-Chem, Inc., Jefferson, AR, USA). Subsequently, the sections were washed 3 times with PBS and dried overnight at room temperature. Following drying, samples were cleared with xylene, a coverslip was added using DPX Mountant (Electron Microscopy Sciences, Hatfield, PA, USA) and visualized using a fluorescence microscope (Olympus Corporation). A total of 3 sections per rat were examined and imaged in parallel for counting Fluoro-Jade B-positive cells using ImageJ software, version 2 (National Institutes of Health).
Statistical analysis. All data are presented as the mean ± standard error of the mean. GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) was used for all statistical analysis. All data were analyzed using one-way analysis of variance. The significance of differences among experimental groups was determined by Fisher's least significant difference post-test and P<0.05 was considered to indicate a statistically significant difference.
Results
Expression of pannexin proteins in rat brain tissues at various time points following ICH.
Pannexin-1 was expressed in the ipsilateral and contralateral cortices in the sham and ICH groups at each of the six time points (Fig. 1C and D) . However, compared with the sham group, the expression levels of Pannexin-1 were significantly higher at 48 and 72 h (P<0.01), as well as at 7 days (P<0.05) following ICH; the expression of Pannexin-1 peaked at 48 h post-ICH. Although Pannexin-2 and Pannexin-3 were also expressed in ICH groups at each time point and in the sham group (Fig. 1C) , there was no significant difference between the two groups (P>0.05; Fig. 1E and F) . Immunofluorescence analysis confirmed that the expression of Pannexin-1 protein in the rat brain neurons gradually increased over time and peaked 48 h post-ICH (Fig. 2) . Conversely, the expression levels of Pannexin-2 and Pannexin-3 at each time point revealed no significant differences between ICH and sham groups (Fig. 1C-F) .
CBX treatment improves cognitive function in rats post-ICH.
Following ICH, rats treated with CBX demonstrated significantly improved activity and appetite compared with the ICH-only group. The total combined score of the ICH-only group was significantly higher than that of sham group (P<0.01). However, neurological scores of the CBX-L and CBX-H treatment groups were markedly lower than the ICH group (P<0.05 and P<0.01, respectively). As shown in Table II , the mean neurological scores were 0.61 (sham group), 3.01 (ICH-only group), 2.11 (ICH + CBX-L group) and 1.87 (ICH + CBX-H group).
CBX treatment reduces brain edema and BBB injury post-ICH.
Brain water content was calculated using the wet/dry weight method. Compared with the sham group, the brain water content was significantly higher in the ICH-only group (P<0.05; Fig. 3A) . However, brain water content of the ICH + CBX-L and ICH + CBX-H groups was lower than in the ICH-only group (P<0.05 and P<0.01, respectively; Fig. 3A) . To evaluate the effects of CBX treatment on BBB integrity following ICH, the protein expression levels of albumin were detected by western blot analysis (Fig. 3B) . The results suggested that CBX treatment could reduce the leakage of albumin content in brain tissue which indicated that CBX treatment may attenuate BBB injury after ICH (Fig. 3B and C) . In addition, CBX treatment also reduced ICH-induced increase in the level of active-caspase3, which indicated that CBX treatment may attenuate brain cell apoptosis following ICH (Fig. 3B and D) .
CBX treatment inhibits neuronal apoptosis and neuronal degeneration in rat brain tissues following ICH.
Neuronal apoptosis was detected by TUNEL staining in each of the four treatment groups. The results indicated that the rate of apoptosis in neurons was significantly higher in the ICH-only group compared with the sham group (P<0.01), whereas the number of apoptotic neurons in the CBX-L and CBX-H treatment groups was significantly lower than in the ICH-only group (P<0.05 and P<0.01, respectively; Fig. 4A and B) . Results of Fluoro-Jade B assay revealed that the rate of neuronal degeneration was markedly increased in the ICH-only group compared with the sham group (P<0.01). However, the rates of neuronal degeneration in the CBX-L or CBX-H groups were significantly lower than that in the ICH-only group (P<0.05 and P<0.01, respectively; Fig. 4C and D) . Western blot analysis confirmed that the expression levels of active-caspase-3 protein were significantly higher in the ICH-only group compared with the sham group (P<0.05; Fig. 3B and D) . However, the expression levels of active-caspase-3 were significantly lower in the ICH + CBX-H treatment group compared with the ICH-only group (P<0.05). There was no significant difference in the expression of active-caspase-3 between the CBX-L treatment group and the ICH-only group (P>0.05; Fig. 3B and D) .
Discussion
Pannexin-1 is a member of the vertebrate pannexin family of gap junction proteins, which was identified after the connexins and exhibits sequence homology with the invertebrate innexins (6). Pannexin-1 is able to form functional gap junctions when expressed in paired Xenopus oocytes, and forms unconjugated hemichannels in cultured neurons and glial cells. The hemichannels are typically closed under resting conditions and permit Ca 2+ and ATP flux when they are open (7) . Numerous studies have reported that the pannexins may form hemichannels in the cell membrane and mediate the release of ATP, the transmission of intercellular Ca 2+ waves, the regulation of blood flow, immune responses and other physiological functions (8, 20) . Pannexins are also involved in inflammation, cancer, cerebral ischemia, epilepsy and other pathologies (8, 20, 21) .
ICH is a devastating disease that is associated with high mortality, and there are no effective treatments to reduce mortality and to improve the outcome for survivors (22) . Nerve injury after ICH is complex. Initial damage is due to the mechanical force induced by formation of the hematoma. Subsequent hematoma expansion, edema and inflammation cause further damage to brain tissues (23) . Excitatory amino acid toxicity is a major factor in secondary brain injury following ICH, and glutamate is the primary excitatory neurotransmitter (24) . Following ICH, high concentrations of glutamate cause excessive activation of NMDARs, which leads to a large increase in Ca 2+ influx, thus triggering a series of neurotoxic cascades (25, 26) . Animal experiments have revealed that the glutamate concentration sharply increases in tissues surrounding a hematoma within 3 h following ICH and peaks at 12 h post-ICH (25) . However, as the volume of the hematoma decreased due to absorption 48-72 h post-ICH, the glutamate concentration also significantly decreased, although it remained higher than the sham group. Pannexin-1 is one of the primary downstream proteins of NMDAR. A previous study revealed that, following repeated or prolonged stimulation, postsynaptic NMDARs induced a secondary inward current (9) . A Pannexin-l specific inhibitory peptide was able to block the inward current, indicating that NMDARs can activate Pannexin-1 hemichannels. Pannexin-1 hemichannels open in response to depolarization, hypoxia and mechanical stress. When open, they permit a large efflux of ATP, which can bind to the P2Y subclass of purinergic receptors present on vascular endothelial cells and red blood cells. The binding of ATP leads to the release of more ATP, diffusion of intracellular Ca 2+ and the release of nitric oxide directly into the vascular smooth muscle cells, which promotes vasodilation and increases blood flow (27) . The present study demonstrated that the expression of Pannexin-1 increased over time following ICH, peaking at 48 h post-ICH; the delay in expression relative to the peak time point of increased glutamate concentration (12 h post-ICH) is probably because Pannexin-1 is downstream of NMDAR signaling.
CBX is a traditional anti-ulcer drug, but it also exhibits anti-inflammatory effects by stimulating the adrenal glands or enhancing endogenous corticosteroids (28) . CBX is a broad-spectrum gap junction inhibitor that permeates the BBB (29) . CBX binds directly to gap junction channels, which results in a conformational change in the gap junction and the closing of hemichannels (30) . A previous study revealed that CBX effectively reduces the depolarization-induced pannexin hemichannel current in Xenopus oocyte assays, and the effect was concentration-dependent (20) . Another study compared the effects of compounds known to inhibit cation and anion channels, and demonstrated that CBX was the most effective inhibitor of Pannexin-1 hemichannels in mammalian cell lines (31) . The suppressive effect of CBX was rapid and readily reversible. These results suggested that CBX may act directly on Pannexin-1 hemichannels. To confirm this finding, further studies are necessary in the future.
Inhibition of gap junctions may serve a neuroprotective role, which has been demonstrated in several in vitro and in vivo models of nerve injury. One study demonstrated that CBX significantly reduced the activation of caspase-3 and decreased neuronal death in hippocampal slice cultures after oxygen-glucose deprivation for 60 min (11) . Using an intrauterine hypoxic-ischemic model, it was revealed that treatment with CBX significantly reduced newborn cub mortality and improved long-term developmental defects (11). However, there have been almost no studies on the effects of gap junction inhibitors on secondary brain injury following ICH. One study demonstrated that intravenous and intraperitoneal injections of CBX significantly reduced seizure severity in rats that were genetically susceptible to epilepsy; the effect was dose-dependent within the range of 5-30 mg/kg CBX (16) . Therefore, CBX may effectively provide neuroprotection and merits further study. The present study, to the best of our knowledge, is the first to investigate the effect of gap junction inhibition on secondary brain injury, and suggested that inhibition of Pannexin-1 may be a target for the treatment of ICH.
In conclusion, the present study confirmed that Pannexin-1 expression was increased following ICH. Furthermore, the elevated expression of Pannexin-1 served an important role in cognitive dysfunction post-ICH. In addition, CBX inhibition of Pannexin-1 effectively reduced ICH-induced brain edema and improved cognitive function. CBX also significantly reduced the expression levels of active-caspase-3 and decreased neuronal apoptosis and degeneration. Results of the present study indicated that CBX may have a protective role in brain damage following ICH.
